Rehmann Capital Advisory Group trimmed its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 6.0% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 155,207 shares of the biopharmaceutical company's stock after selling 9,918 shares during the quarter. Rehmann Capital Advisory Group's holdings in Pfizer were worth $3,933,000 at the end of the most recent reporting period.
Several other hedge funds also recently added to or reduced their stakes in the business. Clarity Asset Management Inc. purchased a new stake in shares of Pfizer during the 4th quarter worth about $27,000. Gould Capital LLC boosted its stake in shares of Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after acquiring an additional 493 shares in the last quarter. North Capital Inc. purchased a new stake in shares of Pfizer during the 1st quarter worth about $28,000. Bernard Wealth Management Corp. purchased a new stake in shares of Pfizer during the 4th quarter worth about $30,000. Finally, Curio Wealth LLC purchased a new stake in shares of Pfizer during the 4th quarter worth about $32,000. 68.36% of the stock is owned by hedge funds and other institutional investors.
Pfizer Stock Down 0.2%
Shares of NYSE:PFE traded down $0.06 on Wednesday, hitting $25.56. 38,339,365 shares of the company's stock were exchanged, compared to its average volume of 41,784,445. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.96 and a current ratio of 1.26. The firm's 50-day moving average is $23.80 and its 200 day moving average is $24.81. The company has a market capitalization of $145.32 billion, a PE ratio of 18.52, a P/E/G ratio of 0.92 and a beta of 0.58. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $31.54.
Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping the consensus estimate of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The firm had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. During the same period last year, the business earned $0.82 EPS. Pfizer's revenue for the quarter was down 7.8% compared to the same quarter last year. Sell-side analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.
Pfizer Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be paid a dividend of $0.43 per share. The ex-dividend date is Friday, July 25th. This represents a $1.72 annualized dividend and a yield of 6.73%. Pfizer's dividend payout ratio is currently 124.64%.
Analyst Ratings Changes
A number of brokerages recently weighed in on PFE. BMO Capital Markets decreased their price target on shares of Pfizer from $36.00 to $30.00 in a research note on Thursday, April 17th. Citigroup increased their price objective on shares of Pfizer from $23.00 to $25.00 and gave the company a "neutral" rating in a report on Wednesday, April 30th. Bank of America increased their price objective on shares of Pfizer from $26.00 to $27.00 and gave the company a "neutral" rating in a report on Wednesday, April 30th. TD Cowen cut their price objective on shares of Pfizer from $32.00 to $28.00 and set a "hold" rating for the company in a report on Tuesday, April 22nd. Finally, Jefferies Financial Group increased their price objective on shares of Pfizer from $32.00 to $33.00 and gave the company a "buy" rating in a report on Wednesday, May 21st. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, six have given a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $28.55.
Get Our Latest Report on PFE
About Pfizer
(
Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Featured Stories
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
